Abbott started at outperform by Oppenheimer, diversified portfolio cited [Seeking Alpha]
Abbott Laboratories (ABT)
Last abbott laboratories earnings: 4/16 07:30 am
Check Earnings Report
US:NYSE Investor Relations:
abbott.com/investors.html
Company Research
Source: Seeking Alpha
Calling Abbott ( ABT ) “a tale of two cities,” Oppenheimer said the company's medtech portfolio, which generates around 45% of its global sales, is growing at 11-13% CAGR, with its non-medtech operations at low single digits to mid-single digits CAGR due to a litigation overhang on its pediatric nutrition business and dwindling sales for COVID-19 diagnostics. “As these non-medtech headwinds subside, comps become easier in FY26, and top-line composite growth should tick up to low double-digits, along with EBIT margins,” the bank added in its note. Oppenheimer set its price target for Abbott ( ABT ) at $130. More on Abbott Laboratories Abbott's Still Crushing It Abbott Laboratories: Cardiovascular Disease Has Been A Tailwind, But Things Could Change Abbott Laboratories: A Dividend Aristocrat To Buy Now WHO approves first mpox diagnostic test for emergency use Abbott, Reckitt trial over infant formula safety starts in Missouri: report Recommended For You Comments M
Show less
Read more
Impact Snapshot
Event Time:
ABT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABT alerts
High impacting Abbott Laboratories news events
Weekly update
A roundup of the hottest topics
ABT
News
- Cardiac Marker Tests Pipeline Report Featuring 230+ Companies and Prospective Products by Stages of Development, Segments, Region and Countries, Regulatory Path [Yahoo! Finance]Yahoo! Finance
- 4 Healthcare Technology Innovators to Invest in Before the New Year [Yahoo! Finance]Yahoo! Finance
- Reasons to Retain ABT Stock in Your Portfolio Now [Yahoo! Finance]Yahoo! Finance
- 2 Top Dividend Stocks to Buy and Hold Through 2025 and Beyond [Yahoo! Finance]Yahoo! Finance
- ABT Stock Up on First Successful LBBAP Procedures With AVEIR Pacemaker [Yahoo! Finance]Yahoo! Finance
ABT
Earnings
- 10/16/24 - Beat
ABT
Sec Filings
- 11/15/24 - Form 8-K
- 11/4/24 - Form 144
- 10/31/24 - Form 10-Q
- ABT's page on the SEC website